Journal
ANNALS OF ONCOLOGY
Volume 20, Issue 11, Pages 1818-1823Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdp209
Keywords
chemotherapy; p53; pRb; prognosis; triple-negative breast cancer
Categories
Funding
- Pallotti's Legacy for Cancer Research
- MIUR
- Centro Interdipartimentale per la Ricerca sul Cancro Giorgio Prodi'', University of Bologna
Ask authors/readers for more resources
Patients and methods: pRb status was prospectively evaluated by immunocytochemistry in 518 consecutive patients with complete receptor information. The predictive value of pRb status in TNBCs was determined according to the adjuvant therapeutic treatments. Results: Fifty-three tumors were identified as TNBCs. The prevalence of pRb loss was significantly higher in TNBCs than in the other cancer subtypes. All patients with TNBCs lacking pRb and treated with systemic chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) were disease free at a medium follow-up time of 109 months, whereas the clinical outcome of those expressing pRb was significantly poorer (P = 0.008). Analysis of disease-free survival including the established anatomo-clinical prognostic parameters indicated pRb loss as the only significant predictive factor. Conclusions: pRb loss is much more frequent in TNBCs than in the other breast cancer subtypes. Patients with TNBCs lacking pRb had a very favorable clinical outcome if treated with conventional adjuvant chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available